Costal Chondrosarcoma in Childhood: Case Report

Malakhat Jahangir Sultanova¹ and Mehriban Musa Sariyeva^1,

¹Diagnostic Radiology Department, Azerbaijan Medical University, Educational-Surgery Clinic

Cite this paper

Malakhat Jahangir Sultanova and Mehriban Musa Sariyeva. Costal Chondrosarcoma in Childhood: Case Report. American Journal of Medical Case Reports. 2022; 10(1):17-21. doi: 10.12691/AJMCR-10-1-6

Abstract

Costal chondrosarcoma is characterized by a high locoregional invasion potential. Because more chondrosarcomas are resistant to chemotherapy and radiation therapy, the main treatment is based on surgery. Radiologic evaluation of patients and confirmatory biopsy of tissue plays a great role in determining localization, spread, invasion, and treatment options. Chondrosarcomas which arise from the axial skeleton have a poor prognosis. Costal chondrosarcomas in pediatric patients are not well discussed in the literature and due to its proximity of organs in the thoracic cavity, carries great risk for complications. Clinical presentation can be unpredictable. Low cost, accessibility, quick examination time makes X-rays a preferable inspection tool to detect the disease, but the important thing here is to examine each chest radiograph precisely, otherwise, the result may be misleading. Costal Chondrosarcoma in an 8-month-old female is a rare case and is covered in this case report.

Keywords

chondrosarcoma, cartilage tumor, costal tumors, chest tumor, pediatric oncology

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	D. Bacha, A. Ayadi-Kaddour, S. Fenniche, A. Marghli, T. Kilani, F. El Mezni, Costal chondrosarcoma. Report of five cases, Orthopaedics & Traumatology: Surgery & Research, Volume 95, Issue 2,2009,Pages 164-169.
[2]	Angelini A, Guerra G, Mavrogenis AF, et al. Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 2012; 106: 929.
[3]	Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40: 818.
[4]	BjÃrnsson J, McLeod RA, Unni KK, et al. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998; 83: 2105.
[5]	Soft tissue and bone tumors. In WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020.
[6]	Bindiganavile S, Han I, Yun JY, Kim HS. Long-term Outcome of Chondrosarcoma: A Single Institutional Experience. Cancer Res Treat 2015; 47:897.
[7]	Fromm J, Klein A, Baur-Melnyk A, et al. Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer 2018; 18: 849.
[8]	van Praag Veroniek VM, Rueten-Budde AJ, Ho V, et al. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol 2018; 27: 402.
[9]	Bovée JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumors and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010; 10: 481.
[10]	Bovée JV. Multiple osteochondromas. Orphanet J Rare Dis 2008; 3: 3.
[11]	Schmale GA, Conrad EU 3rd, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 1994; 76: 986.
[12]	Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet 1995; 55: 43.
[13]	Peterson HA. Multiple hereditary osteochondromata. Clin Orthop Relat Res 1989; 222.
[14]	Pedrini E, Jennes I, Tremosini M, et al. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of “protective” and “risk” factors. J Bone Joint Surg Am 2011; 93: 2294.
[15]	Altay M, Bayrakci K, Yildiz Y, et al. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci 2007; 12:415.
[16]	Ahmed AR, Tan TS, Unni KK, et al. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 2003; 193.
[17]	Pierz KA, Womer RB, Dormans JP. Pediatric bone tumors: osteosarcoma Ewing’s sarcoma, and chondrosarcoma associated with multiple hereditary osteochondromatosis. J Pediatr Orthop 2001; 21: 412.
[18]	Silver C, Jüppner H. Ollier disease. Orphanet J Rare Dis 2006; 1: 37.
[19]	Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas are associated with Ollier's disease. Cancer 1987; 59:1376.
[20]	Schwartz HS, Zimmerman NB, Simon MA, et al. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987; 69:269.
[21]	Albregts AE, Rapini RP. Malignancy in Maffucci's syndrome. Dermatol Clin 1995; 13:73.
[22]	Verdegaal SH, Bovée JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011; 16: 1771.
[23]	Pannier S, Legeai-Mallet L. Hereditary multiple exostoses and enchondromatosis. Best Pract Res Clin Rheumatol 2008; 22: 45.
[24]	Murphey MD, Walker EA, Wilson AJ, et al. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 2003; 23: 1245.
[25]	Leerapun T, Hugate RR, Inwards CY, et al. Surgical management of conventional grade 1 chondrosarcoma of long bones. Clin Orthop Relat Res 2007; 463: 166.
[26]	van der Geest IC, de Valk MH, de Rooy JW, et al. Oncological and functional results of cryosurgical therapy of enchondromas and chondrosarcomas grade 1. J Surg Oncol 2008; 98: 421.
[27]	Donati D, Colangeli S, Colangeli M, et al. Surgical treatment of grade I central chondrosarcoma. Clin Orthop Relat Res 2010; 468: 581.
[28]	Bauer HC, Brosjà O, Kreicbergs A, Lindholm J. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand 1995; 66: 283.
[29]	Aarons C, Potter BK, Adams SC, et al. Extended intralesional treatment versus resection of low-grade chondrosarcomas. Clin Orthop Relat Res 2009; 467: 2105.
[30]	Streitb ürger A, Ahrens H, Balke M, et al. Grade I chondrosarcoma of bone: the Münster experience. J Cancer Res Clin Oncol 2009; 135:543.
[31]	Soft tissue and bone tumors. In WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020.
[32]	Bernard SA, Murphey MD, Flemming DJ, Kransdorf MJ. Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology 2010; 255: 857.
[33]	Lee FY, Yu J, Chang SS, et al. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. J Bone Joint Surg Am 2004; 86-A: 2677.
[34]	Kerr DA, Lopez HU, Deshpande V, et al. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol 2013; 37: 787.
[35]	Mosier SM, Patel T, Strenge K, Mosier AD. Chondrosarcoma in childhood: the radiologic and clinical conundrum. J Radiol Case Rep. 2012; 6(12): 32-42.
[36]	Puri A. Chondrosarcomas in children and adolescents. EFORT Open Rev. 2020; 5(2): 90-95. Published 2020 Feb 26.
[37]	Zamora T, Urrutia J, Schweitzer D, Amenabar PP, Botello E. Do Orthopaedic Oncologists Agree on the Diagnosis and Treatment of Cartilage Tumors of the Appendicular Skeleton? Clin Orthop Relat Res. 2017 Sep; 475(9): 2176-2186.